[临床][常规进展]Alliance Foundation Trials与Natera宣布启动AFT-70 NAVIGATE全球随机III期试验，评估Genentech口服SERD giredestrant联合Signatera MRD指导的CDK4/6抑制剂治疗
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Alliance Foundation Trials（AFT）与Natera宣布启动AFT-70 NAVIGATE，一项评估MRD指导治疗策略的随机III期试验，针对中高危ER阳性/HER2阴性早期乳腺癌患者。 公司：Alliance Foundation Trials 相关资产：giredestrant、Signatera Genome 适应症：ER阳性/HER2阴性早期乳腺癌 阶段：III期临床试验 融资性质：不适用 来源：BioSpace · 新闻稿（https://www.biospace.com/press-releases/alliance-foundation-trials-and-natera-announce-aft-70-navigate-a-global-randomized-phase-iii-trial-evaluating-genentechs-oral-selective-estrogen-receptor-degrader-serd-with-signatera-mrd-guided-cdk4-6-inhibitor-therapy-in-breast-cancer）
来源：BioSpace · 新闻稿 · biospace.com
正在验证登录状态…